1
|
Long Q, An X, Chen M, Wang N, Sui S, Li Y, Zhang C, Lee K, Wang X, Tian T, Pan Y, Qiu H, Xie F, Deng W, Zheng F, He L. PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer. Front Oncol 2020; 10:568015. [PMID: 33117697 PMCID: PMC7576680 DOI: 10.3389/fonc.2020.568015] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 09/04/2020] [Indexed: 12/17/2022] Open
Abstract
Abnormal expression or mutation of RNA splicing proteins are widely observed in human cancers. Here, we identified poly(U) binding splicing factor 60 (PUF60) as one of the most differentially expressed genes out of 97 RNA splicing proteins between normal and bladder cancer tissues by bioinformatics analysis of TCGA bladder cancer expression data. The expression of PUF60 was significantly higher in tumor tissues, while high PUF60 expression was associated with malignant phenotypes of bladder cancer and shorter survival time. Moreover, we identified aurora kinase A (AURKA) as a new downstream target of PUF60 in bladder cancer cells. PUF60 knockdown significantly inhibited cell viability and colony formation capacity in bladder cancer cells, whereas AURKA overexpression reversed this inhibition effect. Overexpression of PUF60 significantly promoted cell viability and colony formation in bladder cancer cells, while treatment with AURKA specific inhibitor reversed this promotive effect. Mechanistically, PUF60 specifically bound to the AURKA promoter, thereby activating its transcription and expression. Furthermore, we showed that there was a significant positive correlation between PUF60 and AURKA expression in bladder cancer tissues, and PUF60 and AURKA expression contributed to tumor progression and malignant phenotypes in the patients with bladder cancer. Collectively, these results indicate that the PUF60/AURKA axis plays a key role in regulating tumorigenesis and progression of bladder cancer, and may be a potential prognostic biomarker and therapeutic target for bladder cancer patients.
Collapse
Affiliation(s)
- Qian Long
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Xin An
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Miao Chen
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Nan Wang
- College of Life Science, Jiaying University, Meizhou, China
| | - Silei Sui
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China
| | - Yixin Li
- The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
| | - Changlin Zhang
- The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Kaping Lee
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Xiaonan Wang
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Tian Tian
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yangxun Pan
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Huijuan Qiu
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.,College of Life Science, Jiaying University, Meizhou, China.,Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.,The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.,The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.,The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Fangyun Xie
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Wuguo Deng
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Fufu Zheng
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Liru He
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| |
Collapse
|
2
|
Puttamallesh VN, Deb B, Gondkar K, Jain A, Nair B, Pandey A, Chatterjee A, Gowda H, Kumar P. Quantitative Proteomics of Urinary Bladder Cancer Cell Lines Identify UAP1 as a Potential Therapeutic Target. Genes (Basel) 2020; 11:genes11070763. [PMID: 32650368 PMCID: PMC7397020 DOI: 10.3390/genes11070763] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 05/26/2020] [Accepted: 05/28/2020] [Indexed: 12/25/2022] Open
Abstract
Bladder carcinoma (BC) incidence and mortality rates are increasing worldwide. The development of novel therapeutic strategies is required to improve clinical management of this cancer. Aberrant protein expression may lead to cancer initiation and progression. Therefore, the identification of these potential protein targets and limiting their expression levels would provide alternative treatment options. In this study, we utilized a liquid-chromatography tandem mass spectrometry-based global proteomics approach to identify differentially expressed proteins in bladder cancer cell lines. A total of 3913 proteins were identified in this study, of which 479 proteins were overexpressed and 141 proteins were downregulated in 4 out of 6 BC cell lines when compared with normal human urothelial cell line (TERT-NHUC). We evaluated the role of UDP-N-acetylhexosamine pyrophosphorylase (UAP1) in bladder cancer pathogenesis. The silencing of UAP1 led to reduction in proliferation, invasion, colony formation and migration capability of bladder cancer cell lines. Thus, our study reveals UAP1 as a promising therapeutic target for bladder cancer.
Collapse
Affiliation(s)
- Vinuth N. Puttamallesh
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;
| | - Barnali Deb
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Manipal Academy of Higher Education, Madhav Nagar, Manipal 576104, India
| | - Kirti Gondkar
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;
| | - Ankit Jain
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
| | - Bipin Nair
- Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;
| | - Akhilesh Pandey
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Manipal Academy of Higher Education, Madhav Nagar, Manipal 576104, India
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
- Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA
- Center for Molecular Medicine, National Institute of Mental Health and Neurosciences, Bangalore 560029, India
| | - Aditi Chatterjee
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;
- Manipal Academy of Higher Education, Madhav Nagar, Manipal 576104, India
| | - Harsha Gowda
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;
- Manipal Academy of Higher Education, Madhav Nagar, Manipal 576104, India
| | - Prashant Kumar
- Institute of Bioinformatics, International Technology Park, Bangalore 560066, India; (V.N.P.); (B.D.); (K.G.); (A.J.); (A.P.); (A.C.); (H.G.)
- Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India;
- Manipal Academy of Higher Education, Madhav Nagar, Manipal 576104, India
- Correspondence: ; Tel.: +91-80-28416140; Fax: +91-80-28416132
| |
Collapse
|
3
|
Wang D, Chen Z, Lin F, Wang Z, Gao Q, Xie H, Xiao H, Zhou Y, Zhang F, Ma Y, Mei H, Cai Z, Liu Y, Huang W. OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells. J Cancer 2018; 9:4684-4695. [PMID: 30588253 PMCID: PMC6299379 DOI: 10.7150/jca.27381] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Accepted: 08/12/2018] [Indexed: 12/14/2022] Open
Abstract
Opa interacting protein 5 (OIP5) has previously been identified as a tumorigenesis gene. The purpose of this study is to explore the role of OIP5 in the progression of bladder cancer (BC). The OIP5 expression and clinical behaviors in bladder cancer were collected from lager database. Our study showed that OIP5 was highly expressed in bladder cancer tissues and cells. Overexpression of OIP5 in tumor patients predicted worse overall survival (OS) and higher histological grade. Vitro and vivo experiments demonstrated that knockdown of OIP5 significantly inhibited cell growth of BC. Scratch assay and transwell assay suggested that migration capacity of BC cells was decreased after knockdown of OIP5. Cisplatin sensitivity assay indicated that depletion of OIP5 increased the sensitivity of BC cells to cisplatin. Finally, we identified 38 overlapping differentially expressed genes (DEGs) between RNA-seq and TCGA analyses which were closely linked to OIP5. Bioinformatics analysis showed that these DEGs enriched in oocyte meiosis, fanconi anemia pathway, cell cycle, and microRNAs regulation. TOP2A, SPAG5, SKA1, EXO1, TK1 were confirmed to associated with bladder cancer development. Our study suggests that OIP5 may be a potential biomarker for growth, metastasis and drug-resistance in bladder cancer.
Collapse
Affiliation(s)
- Dailian Wang
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, China
| | - Zhicong Chen
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, China
| | - Fan Lin
- College of pharmacy, Guangdong Pharmaceutical University, Guangdong, China
| | - Ziqiang Wang
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
| | - Qunjun Gao
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
| | - Haibiao Xie
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
| | - Huizhong Xiao
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
| | - Yifan Zhou
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
| | - Fuyou Zhang
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
| | - Yingfei Ma
- Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
| | - Hongbin Mei
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, China
| | - Zhiming Cai
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
- Carson International Cancer Center, Shenzhen University School of Medicine, Shenzhen, China
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, China
| | - Yuchen Liu
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, China
| | - Weiren Huang
- Department of Urology, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangdong, China
- Carson International Cancer Center, Shenzhen University School of Medicine, Shenzhen, China
- Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen, China
| |
Collapse
|
4
|
Abstract
目的 探讨血清胸苷激酶1(thymidine kinase 1, TK1)在肝癌患者中的表达水平、对肝癌诊断价值及其对预后的指导意义.
方法 采用免疫印迹增强化学发光法检测77例肝癌患者(肝癌组)、41例肝硬化患者(肝硬化组)和47例健康对照者(对照组)血清TK1水平, 对肝癌组患者随访观察2年, 以死亡为终点事件. 非正态分布的计量资料, 采用中位数和四分位数间距表示, 各组间比较采用非参数检验的Kruskal Wallis检验. 通过ROC曲线和ROC曲线下面积(area under curve, AUC)评价TK1对肝癌的诊断价值. 采用Kaplan-Meier法进行生存分析, Log Rank法进行差异性检验, 以P<0.05为差异有统计学意义.
结果 肝癌组患者血清TK1水平为1.85(0.94-3.755)pmol/L, 较肝硬化组的血清TK1水平0.90(0.56-3.13)pmol/L和对照组的血清TK1水平0.72(0.49-1.07)pmol/L明显升高(P<0.05), 肝硬化组和对照组之间TK1水平无差别. 血清TK1对肝癌有诊断价值, AUC为0.739(P<0.05), 诊断界值为1.105, 敏感性为0.714, 特异性为0.693. 血清TK1的水平和患者年龄、谷草转氨酶(aspartate transaminase, AST)、肝功能分级、BCLC分期、血管侵犯、肿瘤大小、肿瘤个数呈正相关(P<0.05). 血清TK1水平在BCLC分期(C+D)期患者高于BCLC(A+B)期患者(P<0.05).
结论 血清TK1在肝癌患者中升高, 可作为诊断肝癌的血清学标志物之一. TK1的水平和肝细胞癌(hepetocellular carcinoma, HCC)患者年龄、AST、肝功能分级、BCLC分期、血管侵犯、肿瘤大小、肿瘤个数正相关. TK1在BCLC(C+D)期患者高于BCLC(A+B)期肝癌患者, 对判断HCC患者的预后有一定指导意义.
Collapse
|